

[Tick-borne encephalitis vaccine](#)

Essential medicine status

Section:

[19. Immunologicals](#) [19.3. Immunologicals > Vaccines](#)

ATC codes: [J07BA01](#)

EMLc

Indication

Need for immunization against arthropod-borne viral encephalitis ICD11 code: [QC01.1](#)

Medicine type

Biological agent

List type

Core

Formulations

All vaccines should comply with the WHO requirements for biological substances.

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Biological

Wikipedia

[Tick-borne encephalitis vaccine](#)

Summary of evidence and Expert Committee recommendations

WHO immunization policy recommendations are published in vaccine position papers on the basis of recommendations made by the Strategic Advisory Group of Experts on Immunization (SAGE). WHO vaccine position papers are updated three to four times per year. Vaccines listed on the 2019 Model List are those for which there is a recommendation from SAGE and a corresponding WHO position paper as at December 2018. The June 2011 version of the WHO position paper for tick-borne encephalitis vaccine is attached. The most recent versions of the WHO position papers, reflecting the current evidence related to a specific vaccine and the related recommendations, can be accessed at any time on the WHO website at: <http://www.who.int/immunization/documents/positionpapers/en/index.html>. Vaccine recommendations may be universal or conditional (e.g., in certain regions, in some high-risk populations or as part of immunization programmes with certain characteristics). Details are available in the relevant position papers, and in the Summary Tables of WHO Routine Immunization Recommendations available on the WHO website at:

http://www.who.int/immunization/policy/immunization_tables/en/index.html. Selection of vaccines from the Model List will need to be determined by each country after consideration of international recommendations, epidemiology and national priorities.